How to survive cancer, from the man who has beaten the disease five times
Bill Potts from Florida has survived cancer five times: thyroid cancer once and non-Hodgkin lymphoma four times. 'It sounds odd to even say those words. It's such a big number,' he said. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2024 Category: Consumer Health News Source Type: news

Breast cancer fears for almost 1,500 women at 'very high risk' of disease after 'historic' blunder meant they weren't invited for annual NHS check-ups
The error meant women who received radiotherapy treatment for Hodgkin lymphoma between 1962 and 2003 were not contacted for annual breast cancer check ups. (Source: the Mail online | Health)
Source: the Mail online | Health - March 5, 2024 Category: Consumer Health News Source Type: news

‘I feel like myself again’: UCLA clinical trial offers hope for lymphoma patients
In June 2018, actor Hirotaka Matsunaga was supposed to be two weeks away from opening night of “The Swords of Sorrow: BURAI II,” a play set in 1800s Japan. The 39-year-old had been cast as the lead. It was the big break he had been working toward since he moved to the U.S. from Japan more than 20 years ago to pursue his dreams.But his cancer diagnosis and an unsuccessful course of chemotherapy had shut down the play.“Around November 2017, I had acute pain in my stomach for weeks, and it got so bad that it became difficult to eat,” Matsunaga said.After a particularly agonizing dinner, he checked himself into a hosp...
Source: UCLA Newsroom: Health Sciences - March 5, 2024 Category: Universities & Medical Training Source Type: news

The Unique Hell of Getting Cancer as a Young Adult
When I got diagnosed with Stage 3b Hodgkin Lymphoma at age 32, it was almost impossible to process. Without a family history or lifestyle risk factors that put cancer on my radar, I stared at the emergency room doctor in utter disbelief when he said the CT scan of my swollen lymph node showed what appeared to be cancer—and lots of it. A few days away from a bucket list trip to Japan, I’d only gone to the emergency room because the antibiotics CityMD prescribed to me when I was sick weren’t working.I didn’t want to be sick in a foreign country. So when the doctor told me of my diagnosis, the  on...
Source: TIME: Health - February 23, 2024 Category: Consumer Health News Authors: Maria Yagoda Tags: Uncategorized freelance Source Type: news

PET/CT scans ‘crucial’ in patients with NK/T-cell lymphoma
PET/CT has significant advantages over conventional methods for lesion detection and staging in patients with natural killer/T-cell lymphoma, according to a study published December 18 in Heliyon.In a retrospective analysis, a team in Taiyuan, China, found that F-18 FDG-PET/CT was superior for analyzing imaging manifestations of NK/T-cell lymphoma and suggested that the scans can improve treatment plans for patients.“F-18 FDG-PET/CT scanning is crucial in identifying tumor lesions, determining staging, and devising treatment strategies for individuals diagnosed with NK/T-cell lymphoma,” wrote lead author Huixia Geng, M...
Source: AuntMinnie.com Headlines - December 22, 2023 Category: Radiology Authors: Will Morton Tags: Radiation Oncology/Therapy Source Type: news

New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news

New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news

PET/CT predicts patient responses to CAR-T cell therapy
F-18 FDG-PET/CT scans may predict outcomes in patients with large B cell lymphoma undergoing chimeric antigen receptor (CAR) T-cell therapy, according to a presentation delivered November 30 at RSNA. Doris Leithner, MD, of Memorial Sloan-Kettering Cancer Center in New York City, presented a study in which researchers explored whether F-18 FDG-PET/CT imaging features acquired prior to treatment with CAR T-cell therapy were related to patient outcomes. They found the imaging features were strongly associated with death, relapse, and disease progression.“Our results demonstrate that quantitative PET imaging features in LBCL...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: Will Morton Tags: Nuclear Radiology Source Type: news

Was This a Recurrence of Non-Hodgkin ’s Lymphoma or Something Else?
“Go to the emergency room,” the doctor told him after hearing of his trip and fever, rash and whole-body weakness. “You need to be seen.” (Source: NYT Health)
Source: NYT Health - November 20, 2023 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Chikungunya Virus Non-Hodgkin ' s Lymphoma Lyme Disease Joints (Body Part) Source Type: news

First in human trial of new drug raises hopes for patients with relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. (Source: World Pharma News)
Source: World Pharma News - November 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Firefighters Fear the Toxic Chemicals in Their Gear Could Be Causing Cancer
BOSTON (AP) — Boston firefighter Daniel Ranahan had heard about colleagues getting cancer but he was stunned when doctors discovered a tumor in his chest. He was only 30 and had been in the Boston Fire Department less than a decade. But as he investigated his diagnosis of Hodgkin’s lymphoma in October 2020 and sought successful treatment, he learned he and others wore gear that contained the toxic industrial compound PFAS. [time-brightcove not-tgx=”true”] “You always hear about the dangers. You just never think it’s going be you,” said Ranahan, who stopped working due to the...
Source: TIME: Health - September 14, 2023 Category: Consumer Health News Authors: MICHAEL CASEY / AP Tags: Uncategorized wire Source Type: news

McConnell ’ s Bid to Downplay Freezes Undermined by History of Politicians Lying About Their Health
After Senate Minority Leader Mitch McConnell froze during a press conference this month, the Kentucky Republican’s second such episode this summer, his office released a note from the Capitol physician intended to calm those worried about his ability to continue at his job. Dr. Brian Monahan told McConnell in the letter that there was “no evidence that you have a seizure disorder or that you experienced a stroke, TIA or movement disorder such as Parkinson’s disease.” Monahan suggested the episodes may be related to the Leader’s concussion in March or to dehydration.  [time-brightcove n...
Source: TIME: Health - September 11, 2023 Category: Consumer Health News Authors: Mini Racker Tags: Uncategorized Congress Source Type: news

CAR-T Therapy for NHL Treats Concurrent Rheumatic Disease CAR-T Therapy for NHL Treats Concurrent Rheumatic Disease
CAR –T cell therapy for non-Hodgkin lymphoma appeared as safe and effective in patients with rheumatic autoimmune disease as in those without and also improved control of the underlying autoimmunity.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 24, 2023 Category: Allergy & Immunology Tags: Rheumatology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news